泰合 (6467)

About 泰合

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage. The company also develops TAH2211 Buprenorphine/Naloxone sublingual film for opioid addiction, which is in phase I; TAH2231 Naloxone Buccal film for opioid overdose, which is in phase I; TAH9922 Atomoxetine oral liquid, which is in phase I; and TAH9901 Methylphenidate patch for ADHD treatment, which is in phase I. Taho Pharmaceuticals Ltd. was founded in 2010 and is headquartered in Taipei, Taiwan.

Headquarters: Taipei, TW · Employees: 35 · Website: https://www.tahopharma.com

Frequently asked questions about 泰合 (6467)

What is 泰合 (6467)?

泰合 (6467) is a publicly traded company in the Healthcare sector (化學生技醫療), listed on TWSE. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.